| Name | Argent Biopharma Limited NPV (DI) |
|---|---|
| Epic | RGT |
| Isin | AU0000326647 |
| Index | UK250 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 16.75p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £550.49 | Debt ratio | n/a |
| Shares in issue | 3,286.48 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 280.31 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -71000 | 52-week high / low | 16.66p / 550.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Argent Biopharma Limited NPV (DI) |
|---|---|
| Address | 1202 Hay Stree, West Perth, Australia, WA 6005 |
| Telephone | +61 (8)6382 3390 |
| Website | http://www.mgcpharma.com.au/ |
| Director | Position |
|---|---|
| Mr Layton Mills | Non-Executive Director |
| Mr Nativ Segev | Non-Executive Director |
| Mr Daniel Robinson | Non-Executive Director |
| Mr Brett Mitchell | Non-Executive Chairman |
| Mr Roby Zomer | Managing Director and CEO |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/06/23 | 30/06/22 | 30/06/21 |
| Intangible asssets and goodwill | n/a | 3.15 | 7.05 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 7.45 | 12.1 | 14.75 |
| Inventory / work in progress | 1.26 | 1.84 | 0.87 |
| Trade and other receivables | 0.93 | 2.73 | 3.1 |
| Cash and equivalents | 0.24 | 1.89 | 5.51 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 9.88 | 18.56 | 24.24 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 13.26 | 7.71 | 6.07 |
| Long term liabilities | 4.76 | 5.67 | 4.34 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 18.02 | 13.38 | 10.41 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | -8.13 | 5.18 | 13.83 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | n/a | n/a | 84.51 |
| Minority interests | -0.63 | -0.66 | -0.01 |
| Retained earnings | n/a | n/a | -78 |
| Share premium account | n/a | n/a | 7.49 |
| Total equity | -8.13 | 5.18 | 13.83 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -21.1 | -20.56 | -15.79 |
| Pre-tax profit | -21.13 | -20.77 | -15.9 |